Skip to main content
Premium Trial:

Request an Annual Quote

KineMed, Pfizer Renew Metabolic Disease Research Collaboration

Premium

NEW YORK (GenomeWeb News) – KineMed this week announced the renewal of its non-exclusive research collaboration with Pfizer into metabolic disease, and type 2 diabetes in particular.

The collaboration was originally established in 2013 and calls for KineMed to use its dynamic proteomics technology platform to map the impact of potential drug candidates.

KineMed's technology uses wide-scale isotopic labeling and mass spectrometry to track protein activity kinetics, which can elucidate biological pathways and disease processes.

This marks the second renewal of the two firms' collaboration, following an initial renewal announced in March.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.